ES2422081T3 - Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales - Google Patents

Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales

Info

Publication number
ES2422081T3
ES2422081T3 ES02786015T ES02786015T ES2422081T3 ES 2422081 T3 ES2422081 T3 ES 2422081T3 ES 02786015 T ES02786015 T ES 02786015T ES 02786015 T ES02786015 T ES 02786015T ES 2422081 T3 ES2422081 T3 ES 2422081T3
Authority
ES
Spain
Prior art keywords
ser
arg
peptide
medicinal uses
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02786015T
Other languages
English (en)
Inventor
Teruo Nishida
Makoto Inui
M Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2422081T3 publication Critical patent/ES2422081T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Péptido que consiste en la secuencia aminoácida representada por Ser-Ser-Ser-Arg o sus salesfarmacéuticamente aceptables.
ES02786015T 2001-12-03 2002-12-03 Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales Expired - Lifetime ES2422081T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001368103 2001-12-03
PCT/JP2002/012632 WO2003048192A1 (en) 2001-12-03 2002-12-03 Novel peptides and medicinal uses thereof

Publications (1)

Publication Number Publication Date
ES2422081T3 true ES2422081T3 (es) 2013-09-06

Family

ID=19177744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02786015T Expired - Lifetime ES2422081T3 (es) 2001-12-03 2002-12-03 Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales

Country Status (13)

Country Link
US (3) US7232881B2 (es)
EP (2) EP2172474B1 (es)
JP (1) JP4310588B2 (es)
KR (2) KR100967152B1 (es)
CN (1) CN1263770C (es)
CA (1) CA2469134C (es)
CY (1) CY1114330T1 (es)
DK (1) DK1462455T3 (es)
ES (1) ES2422081T3 (es)
PT (1) PT1462455E (es)
SI (1) SI1462455T1 (es)
TW (1) TWI305778B (es)
WO (1) WO2003048192A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006143601A (ja) * 2004-11-16 2006-06-08 Yamato Yakuhin Kk 血液粘度低下剤
KR100861914B1 (ko) * 2006-03-06 2008-10-09 (주)케어젠 인슐린 유사 성장인자―１의 활성을 가지는 펩타이드 및그의 용도
US8022037B2 (en) 2007-01-08 2011-09-20 University Of Southern California Skin wound healing compositions and methods of use thereof
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
KR101163171B1 (ko) 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
US8207118B2 (en) 2009-07-17 2012-06-26 University Of Southern California Skin wound healing compositions and methods of use thereof
JP6125141B2 (ja) 2009-09-25 2017-05-10 株式会社アールテック・ウエノ 点眼剤
JP5707101B2 (ja) * 2009-11-11 2015-04-22 国立大学法人山口大学 消化器疾患治療剤
EP2635293B1 (en) * 2010-11-03 2018-04-04 University of Southern California Skin wound healing compositions and methods of use thereof
CA2977562C (en) * 2015-02-25 2019-12-03 Mackay Memorial Hospital Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
TWI619503B (zh) * 2015-12-14 2018-04-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其用途
KR101869783B1 (ko) * 2016-08-17 2018-06-22 (주)진셀팜 미백 활성이 우수한 펩타이드, 및 이의 용도
US10467113B2 (en) * 2017-06-09 2019-11-05 Hewlett Packard Enterprise Development Lp Executing programs through a shared NVM pool
CN112043818A (zh) * 2020-09-16 2020-12-08 温州医科大学附属第一医院 一种用于皮肤创伤的药物及其制备方法和应用
DE112022005006T5 (de) 2021-10-20 2024-08-08 Tataa Biocenter Ab Verfahren und zusammensetzungen zur detektion mutierter nukleinsäuresequenzen
CN119431550A (zh) * 2024-12-20 2025-02-14 南开国际先进研究院(深圳福田) 一种棕榈酰化的igf-1多肽衍生物及其在促进生发中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
JPS6417489A (en) * 1987-07-13 1989-01-20 Hitachi Ltd Extended substrate
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5104787A (en) 1990-03-05 1992-04-14 Lindstrom Richard L Method for apparatus for a defined serumfree medical solution useful for corneal preservation
US5616562A (en) * 1990-04-27 1997-04-01 Murphy; Christopher J. Methods and compositions using substance P to promote wound healing
JPH0525001A (ja) 1991-07-08 1993-02-02 L Lyndstrom Richard 血清不含有医療用溶液および眼組織の品質を高める方法
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
JP3191038B2 (ja) 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
JP4096115B2 (ja) * 2000-08-10 2008-06-04 輝夫 西田 皮膚創傷治癒促進剤
CA2418976C (en) * 2000-08-10 2011-08-02 Santen Pharmaceutical Co., Ltd. Skin wound healing promoters
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途

Also Published As

Publication number Publication date
US7232881B2 (en) 2007-06-19
EP1462455B1 (en) 2013-04-10
KR100967152B1 (ko) 2010-07-05
PT1462455E (pt) 2013-07-09
EP2172474A1 (en) 2010-04-07
WO2003048192A1 (en) 2003-06-12
CA2469134A1 (en) 2003-06-12
TWI305778B (en) 2009-02-01
KR20050044630A (ko) 2005-05-12
JP2008163044A (ja) 2008-07-17
CN1599748A (zh) 2005-03-23
US20050009752A1 (en) 2005-01-13
SI1462455T1 (sl) 2013-09-30
TW200302108A (en) 2003-08-01
US20110059897A1 (en) 2011-03-10
US8183343B2 (en) 2012-05-22
CN1263770C (zh) 2006-07-12
EP1462455A1 (en) 2004-09-29
CY1114330T1 (el) 2016-08-31
JP4310588B2 (ja) 2009-08-12
KR100993233B1 (ko) 2010-11-10
EP2172474B1 (en) 2013-04-17
US7795222B2 (en) 2010-09-14
DK1462455T3 (da) 2013-07-01
AU2002354188A1 (en) 2003-06-17
CA2469134C (en) 2013-10-29
KR20100002291A (ko) 2010-01-06
US20090005317A1 (en) 2009-01-01
EP1462455A4 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
BR0209434A (pt) Peptìdeos antimicrobianos e composições
HN2003000054A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo (cetpi), a procedimientos de uso y a procedimientos de preparacion de las mismas.
BR9902086A (pt) Formulações farmacêuticas.
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
BR0208183A (pt) Peptìdeo modificado por wt1
DE69925133D1 (de) Pyrrolobenzodiazepine
DE60143984D1 (de) Neue phenylalanin-derivate
BR0306905A (pt) Vacinas de flavivìrus
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DK1290011T3 (da) Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
SE0101932D0 (sv) Pharmaceutical combinations
UY26370A1 (es) "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación".
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
NO20073914L (no) Biologisk aktive peptider
DK1462455T3 (da) Ser-Ser-Ser-Arg-peptid samt medicinske anvendelser deraf
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
BR0315055A (pt) Diamidas de ácido pirimidin-4,6-dicarboxìilco para a inibição seletiva de colagenases
UY27373A1 (es) Formulaciones de interferón beta-humano
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
DK1343896T3 (da) Lille syreoplöseligt sporeprotein og anvendelser deraf